Bixiye
P28-17 New Drug-Related Prior Authorization (PA) with Quantity Limit (QL) Criteria: Hereditary Angioedema
Taariikhda uu dhaqangalayo Barnaamijka: May 25, 2017
Dukumentiyadda & Foomamka Natiijooyinka
Soo bandhiga 2911 - 2920 ee natiijooyinka 3607
Bixiye
P3-17 Added Reimbursement Policies
Taariikhda uu dhaqangalayo Barnaamijka: Jan 27, 2017
Bixiye
P15-17 Change to Administration of Interpreter Services for MHCP Subscribers
Taariikhda uu dhaqangalayo Barnaamijka: : Abr 13, 2017
Bixiye
P34-17 Addition of Drug to the Amitiza (lubiprostone), Linzess (linaclotide), and Trulance (plecanatide) Prior Authorization Program
Taariikhda wax ku ool ah ee barnaamijka: Jun 13, 2017
Bixiye
P27-17 New Drug-Related Prior Authorization (PA) with Quantity Limit (QL) Criteria: Antifungal Agents
Taariikhda uu dhaqangalayo Barnaamijka: May 25, 2017
Bixiye
P58-17 New Drug-Related Prior Authorization with Quantity Limit Criteria: Topical Doxepin
Taariikhda uu dhaqangalayo barnaamijka: Okt 24, 2017
Bixiye
P59-16 Organization Determination Additions for Platinum Blue - Effective January 23, 2017
Taariikhda uu dhaqangalayo Barnaamijka: Des 08, 2016
Faa'iidooyinka & Caymiska
Dukaamaysiga & Barashada
How to Read Your Explanation of Health Care Benefits (EOB) Statement
Bixiye
QP4-25 Commercial Pharmacy Benefit Update: New and Revised Drug-Related Prior Authorization (PA) Requirement Notification, Effective March 1, 2025
Taariikhda uu dhaqangalayo Barnaamijka: Jan 22, 2025
Faa'iidooyinka & Caymiska
2025 SecureBlue Spanish Annual Notice of Changes
SecureBlue Notificación Anual de Cambios para 2025